News
SGHT
3.520
-3.83%
-0.140
Top Brass at Sight Sciences Quietly Cash In on a Wave of Insider Stock Sales
TipRanks · 5h ago
Sight Sciences To Present Data On Two Of Its Proprietary Glaucoma And Dry Eye Technologies, OMNI Surgical System And TearCare System, At 2026 ASCRS Annual Meeting
Benzinga · 2d ago
Sight Sciences to present new TearCare data showing superiority over Restasis at ASCRS
Reuters · 2d ago
Sight Sciences to present at Needham Healthcare Conference fireside chat
Reuters · 4d ago
Arq And 2 Other Promising Penny Stocks
Simply Wall St · 4d ago
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th
Barchart · 4d ago
Analysts Offer Insights on Healthcare Companies: Sight Sciences (SGHT), Atara Biotherapeutics (ATRA) and Rezolute (RZLT)
TipRanks · 4d ago
Sight Sciences Wins Key Patent Ruling in Glaucoma Case
TipRanks · 4d ago
Sight Sciences awarded monetary damages by district court against Alcon
TipRanks · 4d ago
SIGHT SCIENCES: U.S. DISTRICT COURT ISSUED ORDER ON POST-TRIAL MOTIONS IN PATENT INFRINGEMENT CASE AGAINST ALCON ORIGINALLY FILED ON SEP 16, 2021
Reuters · 4d ago
SIGHT SCIENCES: ORDER ON POST-TRIAL MOTIONS PRESERVES JURY'S VERDICT AND AWARDS MONETARY DAMAGES TO CO
Reuters · 4d ago
SIGHT SCIENCES: ORDER AWARDED ONGOING ROYALTY OF 10% OF HYDRUS REVENUE THROUGH NOV 10, 2028
Reuters · 4d ago
Sight Sciences wins court order upholding Hydrus patent verdict, awards $34 million damages
Reuters · 4d ago
U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon
Benzinga · 4d ago
Weekly Report: what happened at SGHT last week (0323-0327)?
Weekly Report · 4d ago
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent
Barchart · 5d ago
Weekly Report: what happened at SGHT last week (0316-0320)?
Weekly Report · 03/23 10:36
Weekly Report: what happened at SGHT last week (0309-0313)?
Weekly Report · 03/16 10:35
Morgan Stanley Sticks to Its Hold Rating for Sight Sciences (SGHT)
TipRanks · 03/11 12:35
Sight Sciences price target lowered to $5 from $6.50 at Citi
TipRanks · 03/11 09:25
More
Webull provides a variety of real-time SGHT stock news. You can receive the latest news about Sight Sciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SGHT
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.